Considering that there is a wide variety of therapies that target cAMP-mediated signaling (Parnell et al., 2015), identifying the key components of the cAMP/Epac1/Rap1b pathway could provide an attractive set of new therapeutic targets for the repositioning or development of antiparasitic drugs against CD. The gene discussed is RAP1B; the disease is Cowden disease.